Pneumacare Announces Departure of CEO
Dr. Bill Mason, Chairman of PneumaCare, commented " Ward has had an outstanding track record at PneumaCare and accomplished a great deal for the business and its investors. This includes taking the reins of the company early on its history and steering it through a difficult but exciting period of funding, product development, regulatory approvals and in 2012, the first distribution and sales in the clinical environment. A key part of this has been gaining CE mark approval for our first two products, setting the foundation for FDA approvals which are expected in early 2013.
Ward has demonstrated his considerable ability to work successfully with early stage companies and will continue doing this in the future. This is where his heart lies, and where his skill set is well suited to leading companies through their sometimes very difficult earliest stages. In the case of PneumaCare, it is because of his efforts in creating the highly innovative quality of our product development infrastructure that the company has received a number of local and international awards. He leaves the company having created a base of clinical collaborations and commercial partnerships which will continue to fuel the Company’s growth. He has been a strong ambassador for PneumaCare.
So all of the Board at PneumaCare wish Ward the very best for the future. He will remain a significant shareholder in PneumaCare and I am sure will continue to provide us input and advice from time to time. "
PneumaCare expects to make an announcement shortly about a new CEO for the Company.
- End -
About PneumaCare
PneumaCare is a Cambridge (UK)-based medical imaging company providing clinicians with innovative respiratory diagnostic and monitoring equipment using novel 3D-imaging technology. Its first two products, Thora-3DI™ and PneumaScan™, are CE mark approved and are already being used in and sold to clinics, pre- and post-operative assessments, drug testing, and device development by both public and private health care providers. Further applications of PneumaCare’s proprietary Structured Light Plethysmography technology, developed in close partnership with the clinical community, include neonatal, critical care, and rehabilitation applications. PneumaCare's technology allows clinicians to make detailed non-invasive measurements of respiratory physiology parameters which are critical as diagnostic tools for the physician.
PneumaCare was founded in 2009 to address directly the needs of respiratory clinicians.
510(k) Approval Pending
For more information please contact:
Dr. Bill Mason
Chairman
PneumaCare Limited
St John’s Innovation Centre
Cowley Road
Cambridge CB4 0WS
United Kingdom
Tel: +44 (0) 1223 703 151
Mob: +44 7785 950134
Twitter: @Pneumacare